DermTech

About:

DermTech develops and commercializes qPCR assays for skin samples using adhesive tape biopsy methods.

Website: http://dermtech.com

Twitter/X: dermtech

Top Investors: Tech Coast Angels, HLM Venture Partners, Western States Investment Group

Description:

DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego. The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).